A Dose Escalation Study Of PF-06939999 In Participants With Advanced Or Metastatic Solid Tumors

Inclusion Criteria:

Histologically or cytologically confirmed locally advanced or metastatic NSCLC, urothelial carcinoma or HNSCC
Progressed after at least 1 line of treatment and no more than 3 lines of treatment
At least one measurable lesion as defined by RECIST version 1.1
ECOG Performance Status 0 or 1
Adequate Bone Marrow Function
Adequate Renal Function
Adequate Liver Function
Resolved acute effects of any prior therapy

Exclusion Criteria:

Known active uncontrolled or symptomatic CNS metastases.
Major surgery, radiation therapy, systemic anti-cancer therapy or investigational drug(s) within 4 weeks prior to study entry.
Active, uncontrolled infection, including COVID-19
Known or suspected hypersensitivity to PF-06939999
Inability to consume or absorb study drug